000			01939 a2200505 4500
005			20250516132119.0
264		0	_c20140127
008			201401s 0 0 eng d
022			_a2045-7634
024	7		_a10.1002/cam4.21 _2doi
040			_aNLM _beng _cNLM
100	1		_aJames, Roshan
245	0	0	_aEGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs. _h[electronic resource]
260			_bCancer medicine _cOct 2012
300			_a114-27 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntibiotics, Antineoplastic _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols
650	0	4	_aCell Proliferation
650	0	4	_aDrug Synergism
650	0	4	_aErbB Receptors _xantagonists & inhibitors
650	0	4	_aHumans
650	0	4	_aMice
650	0	4	_aMice, Inbred BALB C
650	0	4	_aMice, Nude
650	0	4	_aMitogen-Activated Protein Kinases _xantagonists & inhibitors
650	0	4	_aMolecular Targeted Therapy
650	0	4	_aNeoplasm Transplantation
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aSTAT3 Transcription Factor _xantagonists & inhibitors
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aSirolimus _xadministration & dosage
650	0	4	_aTOR Serine-Threonine Kinases _xantagonists & inhibitors
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aVishwakarma, Siddharth
700	1		_aChivukula, Indira V
700	1		_aBasavaraj, Chetana
700	1		_aMelarkode, Ramakrishnan
700	1		_aMontero, Enrique
700	1		_aNair, Pradip
773	0		_tCancer medicine _gvol. 1 _gno. 2 _gp. 114-27
856	4	0	_uhttps://doi.org/10.1002/cam4.21 _zAvailable from publisher's website
999			_c22440704 _d22440704